Aniket D. Kulkarni

Aniket D. Kulkarni

Auto-generated profile, based on publicly available information

Aniket D. Kulkarni

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AKAniket D. Kulkarni
Aniket D. Kulkarni
DJDenise J. Jamieson
Denise J. Jamieson
HJHoward W. Jr. Jones
Howard W. Jr. Jones
DKDmitry M. Kissin
Dmitry M. Kissin
MGMaria F. Gallo
Maria F. Gallo
EAEli Y. Adashi
Eli Y. Adashi
The advent of fertility treatments has led to an increase in the rate of multiple births in the United States. However, the trends in and magnitude of the contribution of fertility treatments to the increase are uncertain.

1 August 2017 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
AKAniket D. Kulkarni
Aniket D. Kulkarni
EAEli Y. Adashi
Eli Y. Adashi
DJDenise J. Jamieson
Denise J. Jamieson
SCSara B. Crawford
Sara B. Crawford
SSSaswati Sunderam
Saswati Sunderam
DKDmitry M. Kissin
Dmitry M. Kissin

26 March 2022 in Journal of Adolescent Health
Verified
Journal Article
Closed access
SMSagar D. Mehta
Sagar D. Mehta
AKAniket D. Kulkarni
Aniket D. Kulkarni
KPKaren Pazol
Karen Pazol
EKEmilia H. Koumans
Emilia H. Koumans

7 December 2023 in Women's Health Issues
Verified
Journal Article
Closed access
KCKathryn M. Curtis
Kathryn M. Curtis
AKAniket D. Kulkarni
Aniket D. Kulkarni
ANAntoinette T. Nguyen
Antoinette T. Nguyen
LZLauren B. Zapata
Lauren B. Zapata
KKKatherine Kortsmit
Katherine Kortsmit
MWMaura K. Whiteman
Maura K. Whiteman

4 July 2024 in Journal of Women's Health
Verified
Journal Article
Closed access
AKAniket D. Kulkarni
Aniket D. Kulkarni
NTNaomi Tepper
Naomi Tepper
CPChirag G. Patel
Chirag G. Patel
MMMichael Monsour
Michael Monsour
HTHeather D. Tevendale
Heather D. Tevendale
EKEmilia H. Koumans
Emilia H. Koumans
Objective: To examine claims for reversible prescription contraceptives and chlamydia and gonorrhea testing among commercially and Medicaid-insured adolescent and young adult (AYA) females in the United States. Methods: Using IBM MarketScan Research Databases, we identified sexually active, nonpregnant AYA (15- to 24-year-old) females enrolled in 2018. We examined claims for reversible prescription contraceptives and chlamydia and gonorrhea testing, using drug names and diagnosis/procedure codes, by age-group in commercially and Medicaid-insured separately and by race/ethnicity in Medicaid-insured. Results: Among 15- to 19-year-old and 20- to 24-year-old females, 67.2% and 67.9% of commercially insured and 57.3% and 54.0% of Medicaid-insured, respectively, had claims for reversible prescription contraceptives in 2018. Across insurance types among both age-groups, the most common claim for contraceptives was prescription for combined oral contraceptives. Among Medicaid-insured 15- to 19-year-olds, claims for contraceptives ranged from 42.6% for Hispanic females to 63.4% for non-Hispanic White females; among Medicaid-insured 20- to 24-year-olds, claims ranged from 50.4% for non-Hispanic Black females to 57.0% for non-Hispanic White females. Approximately half of the commercially and Medicaid-insured females had claims for chlamydia and gonorrhea testing. Non-Hispanic Black females had the highest percentages of claims for chlamydia testing (56.3% among 15- to 19-year-olds and 61.1% among 20- to 24-year-olds) and gonorrhea testing (61.6% among 15- to 19-year-olds and 64.9% among 20- to 24-year-olds). Conclusion: Approximately, two-thirds of commercially insured and more than half of Medicaid-insured, sexually active, nonpregnant AYA females had claims for reversible prescription contraceptives. Race/ethnicity data were available for Medicaid-insured females, and there were differences in claims for contraceptives and chlamydia and gonorrhea testing by race/ethnicity. Half of the AYA females had claims for chlamydia and gonorrhea testing suggesting missed opportunities.

1 June 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
SRS.Z. Ramos
S.Z. Ramos
VDV. Danilack
V. Danilack
AKA. Kulkarni
A. Kulkarni
MOM. Oliver
M. Oliver
CMC.A. Mathews
C.A. Mathews